Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
79,040.00
(
-0.02%
)
News Focus
News Focus
Post# of 257578
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ronpopeil post# 164769

Wednesday, 07/31/2013 4:26:47 PM

Wednesday, July 31, 2013 4:26:47 PM

Post# of 257578
ENTA is a screaming buy based on valuation, IMO. ABT-450 is a so-so drug, but the economics of ENTA’s partnership with ABBV (#msg-89280314) almost assure that the share price will rise unless a safety problem derails ABBV’s HCV program (#msg-90408583, #msg-90352754). On top of that, you get the NVS partnership for free.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today